Working with Parent Project Muscular Dystrophy and the Duchenne Registry on patient identification and trial awareness efforts ~15,000 children ...
Partnering with Parent Project Muscular Dystrophy to ensure timely access to the trial for eligible patients~15,000 children are living with DMD ...
New research shows how muscular dystrophy (DM1) damages the heart over time, stressing the need for early diagnosis and ...
I’ve been fighting Duchenne muscular dystrophy for 40 years. My brothers Angelo and Antonio died from it at ages 20 and 22, ...
A mother's persistence helps revive an all-but-abandoned drug class and could aid her son and thousands of others with ...
Facioscapulohumeral muscular dystrophy (FSHD) is an inherited disorder characterized by progressive muscle degeneration, initially involving in the face, shoulder, and upper arms and progressing to ...
MDA’s research funding for Dr. Adrian Krainer’s research led to the groundbreaking discovery of SPINRAZA®. FDA Approves High ...
Sidra Medicine, a member of Qatar Foundation, has provided specialised treatment to a child from Egypt diagnosed with ...
The Muscular Dystrophy Association (MDA) celebrates today's announcement that the U.S. Food and Drug Administration (FDA) has approved a High Dose Regimen of SPINRAZA(R) (nusinersen) for the treatment ...
The FSHD Society, a patient-driven organization advancing research and clinical development in facioscapulohumeral muscular dystrophy (FSHD), SOLVE FSHD, a venture philanthropic organization dedicated ...
Myotonic dystrophy type 1 (DM1) is the most common cause of adult-onset muscular dystrophy, a genetic disorder that leads to muscle weakness and wasting, but also affects the brain, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results